Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis

In a cohort of healthy volunteers, cholesterol efflux capacity was correlated with carotid intima–media thickness. In a cohort of patients with or without angiographically confirmed coronary disease, cholesterol efflux capacity predicted coronary disease status. A robust inverse association between...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2011-01, Vol.364 (2), p.127-135
Hauptverfasser: Khera, Amit V, Cuchel, Marina, de la Llera-Moya, Margarita, Rodrigues, Amrith, Burke, Megan F, Jafri, Kashif, French, Benjamin C, Phillips, Julie A, Mucksavage, Megan L, Wilensky, Robert L, Mohler, Emile R, Rothblat, George H, Rader, Daniel J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 135
container_issue 2
container_start_page 127
container_title The New England journal of medicine
container_volume 364
creator Khera, Amit V
Cuchel, Marina
de la Llera-Moya, Margarita
Rodrigues, Amrith
Burke, Megan F
Jafri, Kashif
French, Benjamin C
Phillips, Julie A
Mucksavage, Megan L
Wilensky, Robert L
Mohler, Emile R
Rothblat, George H
Rader, Daniel J
description In a cohort of healthy volunteers, cholesterol efflux capacity was correlated with carotid intima–media thickness. In a cohort of patients with or without angiographically confirmed coronary disease, cholesterol efflux capacity predicted coronary disease status. A robust inverse association between the level of high-density lipoprotein (HDL) cholesterol and the risk of cardiovascular disease has fostered intensive research seeking to target HDL metabolism for therapeutic gain. 1 , 2 However, some findings have called into question the hypothesis that pharmacologic increases in HDL cholesterol levels are necessarily beneficial. Several therapies, including nicotinic acid and fibric acid derivatives, increase HDL cholesterol levels, but linking these increases to clinical risk reduction has proved challenging. 3 , 4 Most strikingly, an inhibitor of cholesteryl ester transfer protein (CETP) was associated with an increase in the number of cardiovascular events, despite a 72% increase . . .
doi_str_mv 10.1056/NEJMoa1001689
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3030449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>840349697</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-7eecdfd81e226dea3bb224d141e68503af0b2ba112941d7cce140f08144f30543</originalsourceid><addsrcrecordid>eNp1kc9vFCEUx4nR2LV69GomJsZLRx8_hmEuJs26tZpVD-qZMAx02TAwhRlj_3tpurbWRA4Q8j58-b73Reg5hjcYGv72y-bT56gwAOaie4BWuKG0Zgz4Q7QCIKJmbUeP0JOc91AWZt1jdEQwIbxpxQp9W--iN3k2KfpqY61fflVrNSnt5quT6txd7Or3JuRyq7ZuilOKs3GhOluCnl0MJ5UKQ3U678r7rP317vJT9Mgqn82zw3mMfpxtvq_P6-3XDx_Xp9tac9LOdWuMHuwgsClmBqNo3xPCBsyw4aIBqiz0pFcYk47hodXaYAYWBGbMUmgYPUbvbnSnpR_NoE2Yk_JySm5U6UpG5eT9SnA7eRF_SgoUGOuKwOuDQIqXS5mCHF3WxnsVTFyyFAwo63jXFvLlP-Q-LimU7qSgXcsJFk2B6htIlzHkZOytFQzyOix5L6zCv_jb_y39J50CvDoAKmvlbVJBu3zH0bbhhMAdN45ZBrMf__Phb4XyqLs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>839762185</pqid></control><display><type>article</type><title>Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Khera, Amit V ; Cuchel, Marina ; de la Llera-Moya, Margarita ; Rodrigues, Amrith ; Burke, Megan F ; Jafri, Kashif ; French, Benjamin C ; Phillips, Julie A ; Mucksavage, Megan L ; Wilensky, Robert L ; Mohler, Emile R ; Rothblat, George H ; Rader, Daniel J</creator><creatorcontrib>Khera, Amit V ; Cuchel, Marina ; de la Llera-Moya, Margarita ; Rodrigues, Amrith ; Burke, Megan F ; Jafri, Kashif ; French, Benjamin C ; Phillips, Julie A ; Mucksavage, Megan L ; Wilensky, Robert L ; Mohler, Emile R ; Rothblat, George H ; Rader, Daniel J</creatorcontrib><description>In a cohort of healthy volunteers, cholesterol efflux capacity was correlated with carotid intima–media thickness. In a cohort of patients with or without angiographically confirmed coronary disease, cholesterol efflux capacity predicted coronary disease status. A robust inverse association between the level of high-density lipoprotein (HDL) cholesterol and the risk of cardiovascular disease has fostered intensive research seeking to target HDL metabolism for therapeutic gain. 1 , 2 However, some findings have called into question the hypothesis that pharmacologic increases in HDL cholesterol levels are necessarily beneficial. Several therapies, including nicotinic acid and fibric acid derivatives, increase HDL cholesterol levels, but linking these increases to clinical risk reduction has proved challenging. 3 , 4 Most strikingly, an inhibitor of cholesteryl ester transfer protein (CETP) was associated with an increase in the number of cardiovascular events, despite a 72% increase . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1001689</identifier><identifier>PMID: 21226578</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Aged ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Biological Transport - drug effects ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular disease ; Carotid Arteries - anatomy &amp; histology ; Carotid Arteries - pathology ; Case-Control Studies ; Cholesterol ; Cholesterol - metabolism ; Coronary Artery Disease - diagnostic imaging ; Coronary Artery Disease - metabolism ; Coronary vessels ; Disorders of blood lipids. Hyperlipoproteinemia ; Foam Cells - metabolism ; General aspects ; Heart attacks ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hypoglycemic Agents - pharmacology ; Lipoproteins, HDL - blood ; Lipoproteins, HDL - metabolism ; Logistic Models ; Medical sciences ; Metabolic diseases ; Middle Aged ; Radiography ; Smoking ; Thiazolidinediones - pharmacology</subject><ispartof>The New England journal of medicine, 2011-01, Vol.364 (2), p.127-135</ispartof><rights>Copyright © 2011 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-7eecdfd81e226dea3bb224d141e68503af0b2ba112941d7cce140f08144f30543</citedby><cites>FETCH-LOGICAL-c627t-7eecdfd81e226dea3bb224d141e68503af0b2ba112941d7cce140f08144f30543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1001689$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/839762185?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,776,780,881,2745,2746,26082,27903,27904,52361,54043,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23756220$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21226578$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khera, Amit V</creatorcontrib><creatorcontrib>Cuchel, Marina</creatorcontrib><creatorcontrib>de la Llera-Moya, Margarita</creatorcontrib><creatorcontrib>Rodrigues, Amrith</creatorcontrib><creatorcontrib>Burke, Megan F</creatorcontrib><creatorcontrib>Jafri, Kashif</creatorcontrib><creatorcontrib>French, Benjamin C</creatorcontrib><creatorcontrib>Phillips, Julie A</creatorcontrib><creatorcontrib>Mucksavage, Megan L</creatorcontrib><creatorcontrib>Wilensky, Robert L</creatorcontrib><creatorcontrib>Mohler, Emile R</creatorcontrib><creatorcontrib>Rothblat, George H</creatorcontrib><creatorcontrib>Rader, Daniel J</creatorcontrib><title>Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In a cohort of healthy volunteers, cholesterol efflux capacity was correlated with carotid intima–media thickness. In a cohort of patients with or without angiographically confirmed coronary disease, cholesterol efflux capacity predicted coronary disease status. A robust inverse association between the level of high-density lipoprotein (HDL) cholesterol and the risk of cardiovascular disease has fostered intensive research seeking to target HDL metabolism for therapeutic gain. 1 , 2 However, some findings have called into question the hypothesis that pharmacologic increases in HDL cholesterol levels are necessarily beneficial. Several therapies, including nicotinic acid and fibric acid derivatives, increase HDL cholesterol levels, but linking these increases to clinical risk reduction has proved challenging. 3 , 4 Most strikingly, an inhibitor of cholesteryl ester transfer protein (CETP) was associated with an increase in the number of cardiovascular events, despite a 72% increase . . .</description><subject>Aged</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Biological Transport - drug effects</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Carotid Arteries - anatomy &amp; histology</subject><subject>Carotid Arteries - pathology</subject><subject>Case-Control Studies</subject><subject>Cholesterol</subject><subject>Cholesterol - metabolism</subject><subject>Coronary Artery Disease - diagnostic imaging</subject><subject>Coronary Artery Disease - metabolism</subject><subject>Coronary vessels</subject><subject>Disorders of blood lipids. Hyperlipoproteinemia</subject><subject>Foam Cells - metabolism</subject><subject>General aspects</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Lipoproteins, HDL - blood</subject><subject>Lipoproteins, HDL - metabolism</subject><subject>Logistic Models</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Radiography</subject><subject>Smoking</subject><subject>Thiazolidinediones - pharmacology</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kc9vFCEUx4nR2LV69GomJsZLRx8_hmEuJs26tZpVD-qZMAx02TAwhRlj_3tpurbWRA4Q8j58-b73Reg5hjcYGv72y-bT56gwAOaie4BWuKG0Zgz4Q7QCIKJmbUeP0JOc91AWZt1jdEQwIbxpxQp9W--iN3k2KfpqY61fflVrNSnt5quT6txd7Or3JuRyq7ZuilOKs3GhOluCnl0MJ5UKQ3U678r7rP317vJT9Mgqn82zw3mMfpxtvq_P6-3XDx_Xp9tac9LOdWuMHuwgsClmBqNo3xPCBsyw4aIBqiz0pFcYk47hodXaYAYWBGbMUmgYPUbvbnSnpR_NoE2Yk_JySm5U6UpG5eT9SnA7eRF_SgoUGOuKwOuDQIqXS5mCHF3WxnsVTFyyFAwo63jXFvLlP-Q-LimU7qSgXcsJFk2B6htIlzHkZOytFQzyOix5L6zCv_jb_y39J50CvDoAKmvlbVJBu3zH0bbhhMAdN45ZBrMf__Phb4XyqLs</recordid><startdate>20110113</startdate><enddate>20110113</enddate><creator>Khera, Amit V</creator><creator>Cuchel, Marina</creator><creator>de la Llera-Moya, Margarita</creator><creator>Rodrigues, Amrith</creator><creator>Burke, Megan F</creator><creator>Jafri, Kashif</creator><creator>French, Benjamin C</creator><creator>Phillips, Julie A</creator><creator>Mucksavage, Megan L</creator><creator>Wilensky, Robert L</creator><creator>Mohler, Emile R</creator><creator>Rothblat, George H</creator><creator>Rader, Daniel J</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110113</creationdate><title>Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis</title><author>Khera, Amit V ; Cuchel, Marina ; de la Llera-Moya, Margarita ; Rodrigues, Amrith ; Burke, Megan F ; Jafri, Kashif ; French, Benjamin C ; Phillips, Julie A ; Mucksavage, Megan L ; Wilensky, Robert L ; Mohler, Emile R ; Rothblat, George H ; Rader, Daniel J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-7eecdfd81e226dea3bb224d141e68503af0b2ba112941d7cce140f08144f30543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Biological Transport - drug effects</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Carotid Arteries - anatomy &amp; histology</topic><topic>Carotid Arteries - pathology</topic><topic>Case-Control Studies</topic><topic>Cholesterol</topic><topic>Cholesterol - metabolism</topic><topic>Coronary Artery Disease - diagnostic imaging</topic><topic>Coronary Artery Disease - metabolism</topic><topic>Coronary vessels</topic><topic>Disorders of blood lipids. Hyperlipoproteinemia</topic><topic>Foam Cells - metabolism</topic><topic>General aspects</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Lipoproteins, HDL - blood</topic><topic>Lipoproteins, HDL - metabolism</topic><topic>Logistic Models</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Radiography</topic><topic>Smoking</topic><topic>Thiazolidinediones - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khera, Amit V</creatorcontrib><creatorcontrib>Cuchel, Marina</creatorcontrib><creatorcontrib>de la Llera-Moya, Margarita</creatorcontrib><creatorcontrib>Rodrigues, Amrith</creatorcontrib><creatorcontrib>Burke, Megan F</creatorcontrib><creatorcontrib>Jafri, Kashif</creatorcontrib><creatorcontrib>French, Benjamin C</creatorcontrib><creatorcontrib>Phillips, Julie A</creatorcontrib><creatorcontrib>Mucksavage, Megan L</creatorcontrib><creatorcontrib>Wilensky, Robert L</creatorcontrib><creatorcontrib>Mohler, Emile R</creatorcontrib><creatorcontrib>Rothblat, George H</creatorcontrib><creatorcontrib>Rader, Daniel J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khera, Amit V</au><au>Cuchel, Marina</au><au>de la Llera-Moya, Margarita</au><au>Rodrigues, Amrith</au><au>Burke, Megan F</au><au>Jafri, Kashif</au><au>French, Benjamin C</au><au>Phillips, Julie A</au><au>Mucksavage, Megan L</au><au>Wilensky, Robert L</au><au>Mohler, Emile R</au><au>Rothblat, George H</au><au>Rader, Daniel J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2011-01-13</date><risdate>2011</risdate><volume>364</volume><issue>2</issue><spage>127</spage><epage>135</epage><pages>127-135</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>In a cohort of healthy volunteers, cholesterol efflux capacity was correlated with carotid intima–media thickness. In a cohort of patients with or without angiographically confirmed coronary disease, cholesterol efflux capacity predicted coronary disease status. A robust inverse association between the level of high-density lipoprotein (HDL) cholesterol and the risk of cardiovascular disease has fostered intensive research seeking to target HDL metabolism for therapeutic gain. 1 , 2 However, some findings have called into question the hypothesis that pharmacologic increases in HDL cholesterol levels are necessarily beneficial. Several therapies, including nicotinic acid and fibric acid derivatives, increase HDL cholesterol levels, but linking these increases to clinical risk reduction has proved challenging. 3 , 4 Most strikingly, an inhibitor of cholesteryl ester transfer protein (CETP) was associated with an increase in the number of cardiovascular events, despite a 72% increase . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>21226578</pmid><doi>10.1056/NEJMoa1001689</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2011-01, Vol.364 (2), p.127-135
issn 0028-4793
1533-4406
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3030449
source MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine
subjects Aged
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Biological Transport - drug effects
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular disease
Carotid Arteries - anatomy & histology
Carotid Arteries - pathology
Case-Control Studies
Cholesterol
Cholesterol - metabolism
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - metabolism
Coronary vessels
Disorders of blood lipids. Hyperlipoproteinemia
Foam Cells - metabolism
General aspects
Heart attacks
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hypoglycemic Agents - pharmacology
Lipoproteins, HDL - blood
Lipoproteins, HDL - metabolism
Logistic Models
Medical sciences
Metabolic diseases
Middle Aged
Radiography
Smoking
Thiazolidinediones - pharmacology
title Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A04%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cholesterol%20Efflux%20Capacity,%20High-Density%20Lipoprotein%20Function,%20and%20Atherosclerosis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Khera,%20Amit%20V&rft.date=2011-01-13&rft.volume=364&rft.issue=2&rft.spage=127&rft.epage=135&rft.pages=127-135&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1001689&rft_dat=%3Cproquest_pubme%3E840349697%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=839762185&rft_id=info:pmid/21226578&rfr_iscdi=true